Eli Lilly and Company (NYSE:LLY) Shares Up 1.1% - Here's Why

Key Points

• Lilly shares rose 1.1% as investors responded to strong GLP-1 momentum: about 700,000 seniors began treatment after new Medicare coverage, with roughly 70% using Lilly products.
• The company is expanding its obesity-drug capacity, reporting early adoption of its Foundayo pill and breaking ground on a planned $6.5 billion Houston manufacturing facility expected to be completed in 2030.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $1,305.25, though competition from Novo Nordisk and recent insider selling remain risks.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price rose 1.1% during mid-day trading on Monday . The stock traded as high as $1,170.90 and last traded at $1,165.62. Approximately 2,200,005 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 3,018,681 shares. The stock had previously closed at $1,152.93.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO David Ricks said approximately 700,000 seniors began GLP-1 treatment after new Medicare coverage launched in July, with about 70% using Lilly medicines. The data suggests Medicare could materially expand the company’s addressable obesity-treatment market. Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage
• Positive Sentiment: Lilly said one-third of new GLP-1 pill patients are taking Foundayo, its oral obesity drug, and that it is increasing production. Strong early adoption could diversify growth beyond injectable treatments and support future revenue. Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo
• Positive Sentiment: The company is breaking ground on a planned $6.5 billion manufacturing facility in Houston, scheduled for completion in 2030. The investment should expand long-term supply capacity for obesity medicines, though it also increases capital spending. Eli Lilly to host groundbreaking of $6.5 billion facility at Houston’s Generation Park
• Positive Sentiment: An updated valuation estimate raised Lilly’s fair value to $1,325.39 from $1,297.31, reflecting continued analyst support for GLP-1 growth. Eli Lilly stock fair value edges higher
• Neutral Sentiment: Lilly completed a clinical study of LY3971297, an early-stage cardio-metabolic candidate. The update advances the pipeline but provided no immediate efficacy or approval catalyst. Lilly’s LY3971297 trial completion signals next steps
• Negative Sentiment: Competitive pressure remains a risk after Novo Nordisk reported Phase 3 CagriSema results that outperformed Lilly’s tirzepatide in weight loss. Novo’s weak market reaction suggests broader concerns about the obesity-drug market, while Lilly’s stock has also recently lagged the broader market. Novo Nordisk falls as competition fears persist

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LLY shares. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Citigroup raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Tuesday, July 7th. Finally, Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,305.25.

Eli Lilly and Company Stock Up 1.1%

The company has a market capitalization of $1.10 trillion, a P/E ratio of 39.11, a PEG ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a 50 day moving average price of $1,176.90 and a 200 day moving average price of $1,077.21.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the prior year, the firm earned $6.31 EPS. The company's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts forecast that Eli Lilly and Company will post 36.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 over the last ninety days. 0.14% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of LLY. Coastal Bridge Advisors LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $2,959,000. Mosaic Family Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after purchasing an additional 1,430 shares during the period. Generali Investments Management Co LLC raised its position in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock worth $12,258,000 after buying an additional 1,521 shares in the last quarter. Moran Wealth Management LLC raised its position in shares of Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock worth $25,072,000 after buying an additional 9,638 shares in the last quarter. Finally, Amundi boosted its stake in Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company's stock valued at $4,649,464,000 after buying an additional 454,549 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.